)
From target to treatment
Transforming promising drug candidates into life-changing medicines.
Therapeutic development Cancer drug discovery beyond target ID and validation
Once a target has been validated and characterized, we initiate a structure or ligand-based hit discovery process. By combining computational modeling and high-throughput screening, we can efficiently identify early hit molecules with the desired activity. Further hit validation of these hits is performed in our proprietary, patient-derived, 2D and 3D tumor models. We also engage with pharmaceutical partners to codevelop promising candidates further in the drug discovery and development pipeline.
)
Hit and lead identification
- Hit screening utilizing cell-free and cell-based assays
- Fragment-based ligand screening
- Hit and lead validation using patient-derived 2D/3D tumor models
- Biophysics-driven virtual ligand screening
- Ligand selection applying statistical learning
- Chemical synthesis of virtual hits
Preclinical and clinical development
Throughout the process of hit and lead development, we use insights gained from our multi-omics and clinical database as well as our patient-derived 2D/3D validation platform. Through in-house efforts and collaborations with pharmaceutical partners, we can progress small and large molecules toward IND and beyond. Notably, in-depth knowledge of the molecular and clinical characteristics of the targeted patient population enables us to design tailor-made clinical trial strategies at an early stage.
:format(webp))
Our global clinical network provides access to experienced clinical sites and the envisaged patients to execute clinical trial strategies.
Precision oncology
“Developing novel therapies is only part of the story. We want to get them to the right patients as quickly as possible.”